Total Payments
$1,214
2024 Payments
$324.18
Companies
12
Transactions
28
Medicare Patients
773
Medicare Billing
$103,695
Payment Breakdown by Category
Food & Beverage$1,204 (99.2%)
Education$10.30 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,204 | 27 | 99.2% |
| Education | $10.30 | 1 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $256.63 | 4 | $0 (2023) |
| Mallinckrodt Hospital Products Inc. | $194.92 | 4 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $150.00 | 1 | $0 (2024) |
| Perspectum Diagnostics Ltd | $123.35 | 1 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $122.80 | 6 | $0 (2024) |
| Gilead Sciences, Inc. | $94.49 | 1 | $0 (2022) |
| Veloxis Pharmaceuticals, Inc. | $76.84 | 3 | $0 (2024) |
| La Jolla Pharmaceutical Company | $70.19 | 1 | $0 (2022) |
| Vifor Pharma, Inc. | $56.01 | 3 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $36.80 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $324.18 | 9 | SANOFI-AVENTIS U.S. LLC ($150.00) |
| 2023 | $559.74 | 13 | Mallinckrodt Hospital Products Inc. ($165.25) |
| 2022 | $220.09 | 5 | Gilead Sciences, Inc. ($94.49) |
| 2018 | $110.01 | 1 | AbbVie, Inc. ($110.01) |
All Payment Transactions
28 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | Veloxis Pharmaceuticals, Inc. | ENVARSUS (Drug) | Food and Beverage | In-kind items and services | $31.95 | General |
| Category: TRANSPLANTATION | ||||||
| 11/17/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $28.60 | General |
| 08/21/2024 | Veloxis Pharmaceuticals, Inc. | ENVARSUS (Drug) | Food and Beverage | In-kind items and services | $23.66 | General |
| Category: TRANSPLANTATION | ||||||
| 08/01/2024 | SANOFI-AVENTIS U.S. LLC | THYMOGLOBULIN (Biological) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Oncology | ||||||
| 04/24/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $24.23 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/17/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: CRITICAL CARE | ||||||
| 04/16/2024 | Veloxis Pharmaceuticals, Inc. | ENVARSUS (Drug) | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: TRANSPLANTATION | ||||||
| 02/28/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.68 | General |
| 02/15/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/13/2023 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: VIROLOGY | ||||||
| 10/04/2023 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/12/2023 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Food and Beverage | In-kind items and services | $13.61 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/08/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.47 | General |
| Category: Gastroenterology | ||||||
| 08/24/2023 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $16.47 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/16/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: Gastroenterology | ||||||
| 08/09/2023 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: Hyperkalemia | ||||||
| 07/18/2023 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Education | In-kind items and services | $10.30 | General |
| Category: CRITICAL CARE | ||||||
| 06/21/2023 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: Hyperkalemia | ||||||
| 05/17/2023 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $154.95 | General |
| Category: CRITICAL CARE | ||||||
| 05/06/2023 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $75.02 | General |
| Category: VIROLOGY | ||||||
| 04/01/2023 | Perspectum Diagnostics Ltd | LiverMultiScan (Device) | Food and Beverage | Cash or cash equivalent | $123.35 | General |
| Category: Radiology | ||||||
| 03/30/2023 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: Hyperkalemia | ||||||
| 12/01/2022 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $15.43 | General |
| Category: CRITICAL CARE | ||||||
| 11/07/2022 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: VIROLOGY | ||||||
| 09/21/2022 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 164 | 615 | $97,403 | $38,811 |
| 2022 | 4 | 133 | 416 | $68,798 | $25,598 |
| 2021 | 9 | 280 | 295 | $474,841 | $24,942 |
| 2020 | 8 | 196 | 209 | $257,165 | $14,345 |
Total Patients
773
Total Services
1,535
Medicare Billing
$103,695
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 37 | 403 | $56,823 | $24,893 | 43.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 51 | 95 | $19,475 | $7,185 | 36.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 58 | 99 | $13,959 | $4,498 | 32.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $7,146 | $2,234 | 31.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 179 | $25,239 | $9,963 | 39.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 68 | $13,804 | $5,443 | 39.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 41 | 65 | $13,325 | $4,869 | 36.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 49 | 93 | $13,113 | $4,683 | 35.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 11 | $3,317 | $638.93 | 19.3% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 56 | 56 | $196,896 | $10,111 | 5.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 43 | 57 | $17,898 | $4,897 | 27.4% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 54 | 55 | $147,290 | $2,355 | 1.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 19 | 19 | $9,063 | $2,233 | 24.6% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 22 | 22 | $51,524 | $1,863 | 3.6% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 19 | 19 | $39,368 | $1,403 | 3.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 21 | 21 | $4,600 | $1,066 | 23.2% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 12 | 12 | $5,040 | $916.92 | 18.2% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2021 | 34 | 34 | $3,162 | $96.96 | 3.1% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Facility | 2020 | 20 | 20 | $69,280 | $3,897 | 5.6% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 34 | 35 | $92,330 | $3,483 | 3.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 25 | 32 | $9,856 | $2,199 | 22.3% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 20 | 20 | $46,140 | $1,522 | 3.3% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 20 | 20 | $6,640 | $1,358 | 20.5% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 12 | 12 | $24,492 | $961.96 | 3.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 14 | 17 | $3,604 | $759.11 | 21.1% |
About Dr. Veron Browne, M.D
Dr. Veron Browne, M.D is a Hepatology healthcare provider based in Shreveport, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/30/2008. The National Provider Identifier (NPI) number assigned to this provider is 1710143631.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Veron Browne, M.D has received a total of $1,214 in payments from pharmaceutical and medical device companies, with $324.18 received in 2024. These payments were reported across 28 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($1,204).
As a Medicare-enrolled provider, Browne has provided services to 773 Medicare beneficiaries, totaling 1,535 services with total Medicare billing of $103,695. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Hepatology
- Other Specialties Gastroenterology
- Location Shreveport, LA
- Active Since 07/30/2008
- Last Updated 05/10/2022
- Taxonomy Code 207RI0008X
- Entity Type Individual
- NPI Number 1710143631
Products in Payments
- TERLIVAZ (Drug) $194.92
- THYMOGLOBULIN (Biological) $150.00
- MAVYRET (Drug) $146.62
- LiverMultiScan (Device) $123.35
- Mavyret (Drug) $110.01
- LOKELMA (Drug) $78.52
- ENVARSUS (Drug) $76.84
- XERAVA (Drug) $70.19
- Veltassa (Drug) $56.01
- XIFAXAN (Drug) $36.80
- LIVTENCITY (Drug) $18.38
- PREVYMIS (Drug) $13.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.